Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042.

Hermida-Prado F, Villaronga MÁ, Granda-Díaz R, Del-Río-Ibisate N, Santos L, Hermosilla MA, Oro P, Allonca E, Agorreta J, Garmendia I, Tornín J, Perez-Escuredo J, Fuente R, Montuenga LM, Morís F, Rodrigo JP, Rodríguez R, García-Pedrero JM.

J Clin Med. 2019 Aug 2;8(8). pii: E1157. doi: 10.3390/jcm8081157.

2.

The multikinase inhibitor EC-70124 synergistically increased the antitumor activity of doxorubicin in sarcomas.

Estupiñan O, Santos L, Rodriguez A, Fernandez-Nevado L, Costales P, Perez-Escuredo J, Hermosilla MA, Oro P, Rey V, Tornin J, Allonca E, Fernandez-Garcia MT, Alvarez-Fernandez C, Braña A, Astudillo A, Menendez ST, Moris F, Rodriguez R.

Int J Cancer. 2019 Jul 1;145(1):254-266. doi: 10.1002/ijc.32081. Epub 2019 Jan 14.

PMID:
30575954
3.

Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia.

Puente-Moncada N, Costales P, Antolín I, Núñez LE, Oro P, Hermosilla MA, Pérez-Escuredo J, Ríos-Lombardía N, Sanchez-Sanchez AM, Luño E, Rodríguez C, Martín V, Morís F.

Mol Cancer Ther. 2018 Mar;17(3):614-624. doi: 10.1158/1535-7163.MCT-17-0530. Epub 2018 Jan 16.

4.

Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma.

Tornin J, Martinez-Cruzado L, Santos L, Rodriguez A, Núñez LE, Oro P, Hermosilla MA, Allonca E, Fernández-García MT, Astudillo A, Suarez C, Morís F, Rodriguez R.

Oncotarget. 2016 May 24;7(21):30935-50. doi: 10.18632/oncotarget.8817.

Supplemental Content

Support Center